Drug Profile
Polyphenon E - Aresus Pharma/Epitome Pharmaceuticals
Alternative Names: Polyphenon E; SB 03; Sinecatechins; VeregenLatest Information Update: 17 Sep 2021
Price :
$50
*
At a glance
- Originator Mitsui Norin; Polyphenon Pharma
- Developer Emory University; Maastricht University; MediGene AG; Polyphenon Pharma; SynCore Biotechnology; Triton Pharma; Will-Pharma
- Class Antineoplastics; Antivirals; Catechins; Herbal medicines
- Mechanism of Action Antioxidants; Immunostimulants; Viral fusion protein inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Genital warts
- Phase II/III Basal cell cancer
- Phase II Prostatic intraepithelial neoplasia
- No development reported Bladder cancer; Head and neck cancer
- Discontinued Actinic keratosis; Angina pectoris; Chronic lymphocytic leukaemia